Summan Piritrexim is a lipid-soluble drug which is as effectise an inhibitor of dihydrofolate reductase as methotrexate. Phase I and II studies have indicated activity in some tumour types. Because of its lipophilicity ue have conducted a phase II study in recurrent high-grade malignant glioma (grades III and IV). Twentyseven patients were treated with 25 mg p.o. three times daily for five consecutive days. repeated weekly. with provision for dose escalation or reduction according to toxicity. Five patients received less than 4 weeks' treatment because of disease progression or death. Twentv-two patients were evaluable for response. One complete and one partial response was seen (duration 262+ and 241 + weeks) and 13 patients had static disease for a median duration of 13 weeks (range 7-35). The major toxicity was myelosuppression. This response rate of 90o of evaluable patients is much lower than that seen for some conventionally used drugs and we conclude that piritrexim is unlikely to be of value in the management of high-grade gliomas.
Piritrexim (2. 4-diamino-6-(2. 5-dimethoxybenzyl) -5-methylpxridol[2.3-dnpvrimidine: BW 301U: PTX) is a lipid-soluble inhibitor of dihydrofolate reductase (DHFR: Duch et al.. 1982 : Sedgick et al.. 1982 : Sigel et al.. 1987 . It enters cells rapidly. is not polyglutamated intracellularly and is as potent an inhibitor of DHFR in vitro as methotrexate (Duch et al.. 1982) . Activity against human tumour cells has been demonstrated using the human tumour cloning assay in lung. ovar-. colon and breast cancer (Neuenfeldt et al.. 1982 : Marshall et al.. 1985 .
Intravenous administration causes peripheral phlebitis and. as oral bioavailabilitv is around 75%o. oral dosing has been recommended (Weiss et al.. 1989) . A phase I study using prolonged oral low-dose schedules has demonstrated an acceptable regimen of 25 mg three times daily for 5 days out of 7 for three consecutive weeks followed by 1 week without PTX (Feun et al.. 1991) . Myelosuppression was the main dose-limiting toxicity. A paediatric phase I study has also been reported (Adamson et al.. 1990) .
Several phase II studies have now been reported. Antitumour activitv has been seen in melanoma (Feun et al.. 1991) . head and neck cancer (Uen et al.. 1992) . soft-tissue sarcoma (Schiesel et al.. 1992 ) and metastatic urothelial cancer (De Wit et al.. 1993a) . Some activity was also seen in non-small-cell lung cancer (Kris et al.. 1987) A total of 226 weekly courses was given in the 27 patients. The median number of courses per patient was 7 (range 1 -27) and the median duration of treatment was 8 weeks (range 1-37). The rarely documented because normalisation of the radiological appearance is unlikely as a result of brain destruction due to tumour, surgery and the attendant changes following radiotherapy. The two long-term responders in this study therefore may be considered as worthwhile responses. More difficult to interpret is the significance of the 59% of patients with static disease. Patients who were entered into the study were on a stable steroid dosage and with prior evidence of relapsing tumour. Disease stability may therefore be interpreted as evidence of some anti-tumour activity of the PTX. but this conclusion needs to be accepted with caution.
The most active drugs reported include BCNU. CCNU.
MeCCNU. PCNU. procarbazine and dacarbazine. for which response rates of 19-50°% have been reported (Lesser et al., 1993) . A newer drug. temozolomide. has been reported to give a response in 5 10 (50%) patients (O'Reilly et al.. 1993 (Kris et al.. 1987 ) and 1 24 (4%) in breast cancer (De Vnres et al.. 1993) . Other studies have reported better response rates in squamous head and neck cancer 9 33 (27%) including three CRs (Uen et al.. 1992) and 7 31 (23%) in malignant melanoma with two CRs (Feun et al.. 1991) . Only in the report on a phase II trial in metastatic urothelial cancer was a high response rate of 11 29 (38%) with one CR seen. but as the authors indicated this is similar to that seen with methotrexate (De Wit et al.. 1993a) .
In this present study the expectation that the lipophilicity of PTX might provide an additional drug with a worthwhile response rate in brain tumours. which might then take its place in a combination regimen with a nitrosourea, has not been justified. In spite of the two good responses. the results of this study are inferior to those reported with other drugs currently available.
